Ibrutinib,Markets and News,API,Ibrutinib,936563-96-1,ANQING CHICO PHARMACEUTICAL

Abstract

Ibrutinib, marketed as Imbruvica, is a Bruton's tyrosine kinase (BTK) inhibitor revolutionizing the treatment of various B-cell malignancies. Developed collaboratively by Pharmacyclics LLC and Janssen Biotech, Inc., it received FDA approval in 2013. This paper provides a comprehensive overview of ibrutinib, detailing its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations. Additionally, it presents speculative sales figures from 2020 to 2024 based on available data and market trends.

Keywords

Ibrutinib, Imbruvica, Bruton's tyrosine kinase inhibitor, chemical properties, market analysis, global sales, generics.

Introduction

Ibrutinib is an oral medication that irreversibly binds to Bruton's tyrosine kinase (BTK), a crucial enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, ibrutinib effectively reduces B-cell proliferation and survival, making it a pivotal treatment for various hematologic cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (WM).

Chemical Properties

Ibrutinib has the chemical formula C25H24N6O2 and a molar mass of approximately 440.5 g·mol−1. Its IUPAC name is 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one. The compound's structure enables selective and irreversible inhibition of BTK, contributing to its efficacy in treating B-cell malignancies.

Development and Approval Timeline

• 2006: Scientists at Celera Genomics identified a BTK inhibitor, PCI-32765, as a tool compound for studying BTK function.

• 2011: Pharmacyclics and Johnson & Johnson co-developed PCI-32765, later named ibrutinib.

• 2013: The FDA approved ibrutinib for treating MCL.

• 2014: Approval expanded to include CLL/SLL.

• 2015-2019: Additional approvals for indications like WM, marginal zone lymphoma, and chronic graft-versus-host disease.

Time on the Market

Since its approval in 2013, ibrutinib has been available for over a decade. Its sustained market presence highlights its significance in hematologic oncology, with ongoing research potentially broadening its therapeutic applications.

Global Sales and Market Competition

In 2022, global sales of Imbruvica (ibrutinib) reached approximately $8.352 billion. citeturn0search2 In 2023, global net revenues were $4.879 billion, reflecting a compound annual growth rate (CAGR) of approximately -9.64% from 2020 to 2023.

The market is competitive, with alternatives like acalbrutinib (Calquence) and zanubrutinib (Brukinsa) offering BTK inhibition with potentially differing side effect profiles. Factors influencing market share include efficacy, safety, cost, and patient preferences.

Generics and Related Developments

As of 2024, generic formulations of ibrutinib have entered markets such as India, enhancing accessibility and affordability. citeturn0search4 In the U.S., Medicare has initiated price negotiations for high-cost drugs, including Imbruvica, aiming to reduce expenditures.

Speculated Sales Figures (2020–2024)

Based on available data and market trends, estimated global sales of Imbruvica are as follows:

• 2020: Approximately $8.0 billion

• 2021: Approximately $8.2 billion

• 2022: Approximately $8.35 billion

• 2023: Approximately $4.88 billion

• 2024: Projected around $5.0 billion

The decline in 2023 sales is attributed to factors such as increased competition and pricing pressures.

Conclusion

Ibrutinib has significantly impacted the treatment landscape for B-cell malignancies since its introduction, offering patients effective therapeutic options. Its market trajectory reflects both its clinical value and the evolving dynamics of the pharmaceutical industry, including competition, pricing strategies, and the introduction of generic alternatives. Ongoing research and market adaptations will continue to shape its role in oncology therapeutics.

Active Pharmaceutical Ingredient
936563-96-1
Ibrutinib, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.